View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

CBRE Global Real Estate Income Fund: 1 director

A director at CBRE Global Real Estate Income Fund maiden bought 46,500 shares at 4.320USD and the significance rating of the trade was 78/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ove...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: December 18, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

BRT Apartments Corp. Completes Debt Refinancings

BRT Apartments Corp. Completes Debt Refinancings GREAT NECK, N.Y., Dec. 17, 2025 (GLOBE NEWSWIRE) -- BRT APARTMENTS CORP. (NYSE: BRT) announced today that it has successfully completed the refinancing of three mortgages mentioned in the Company’s most recent 10-Q filing. The three maturing mortgages in the aggregate amount of $42.7 million and bearing a weighted average interest rate of 4.36% were refinanced through new mortgage debt in the aggregate amount of approximately $71.9 million, with a weighted average remaining term to maturity of approximately nine years and a weighted averag...

 PRESS RELEASE

BRT Apartments Corp. Announces Quarterly Dividend

BRT Apartments Corp. Announces Quarterly Dividend GREAT NECK, New York, Dec. 10, 2025 (GLOBE NEWSWIRE) -- BRT APARTMENTS CORP. (NYSE: BRT) announced today that its Board of Directors declared a quarterly dividend of $0.25 per share. The dividend is payable January 6, 2026, to stockholders of record at the close of business on December 22, 2025. The Company estimates that for federal income tax purposes, all of this dividend will be included in 2026 taxable income and that all of the dividends paid in 2025 will be treated as a return of capital. BRT is a real estate investment trust that ...

 PRESS RELEASE

Ocular Therapeutix™ Announces Plans to Accelerate NDA Submission Timel...

Ocular Therapeutix™ Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI™ in Wet AMD Ocular intends to submit AXPAXLI New Drug Application (NDA) for wet AMD shortly after year one data from SOL-1, if positive SOL-1 topline data remain on track for 1Q 2026 Ocular plans to leverage the 505(b)(2) regulatory pathway for new drug approvals which has the potential to shorten the review timeline for AXPAXLI If approved, AXPAXLI could be the first TKI to be commercialized in wet AMD, with a potential superiority label and best-in-class durability BEDFORD, Mass., Dec. 08, 2025 (GL...

 PRESS RELEASE

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule...

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to eight newly hired non-executive employees. The awards were made as an inducement material to each recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement eq...

 PRESS RELEASE

UMH PROPERTIES, INC. ANNOUNCES ADDITION TO FANNIE MAE CREDIT FACILITY

UMH PROPERTIES, INC. ANNOUNCES ADDITION TO FANNIE MAE CREDIT FACILITY FREEHOLD, NJ, Nov. 25, 2025 (GLOBE NEWSWIRE) -- UMH Properties, Inc. (NYSE: UMH) (TASE: UMH) announced that on November 25, 2025 it completed the addition of seven communities containing 1,765 sites, to its Fannie Mae credit facility through Wells Fargo Bank, N.A., for total proceeds of approximately $91.8 million. This interest-only loan is at a fixed rate of 5.46% with a 9-year term. The proceeds will be used to invest in additional acquisitions, expansions, rental homes and repay higher interest rate debt on a short-...

 PRESS RELEASE

Ocular Therapeutix™ Announces First Patient Randomized in HELIOS-3 Pha...

Ocular Therapeutix™ Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI™ in NPDR First patient randomized into HELIOS-3, which along with HELIOS-2 form the basis of AXPAXLI’s registrational program in non-proliferative diabetic retinopathy (NPDR) HELIOS-2 and HELIOS-3 are global, complementary superiority trials using a novel ordinal diabetic retinopathy severity scale (DRSS) primary endpoint Targeting a broad diabetic retinopathy (DR) label by including patients with non-center-involved diabetic macular edema (non-CI-DME) BEDFORD, Mass., Nov. 24, 2...

 PRESS RELEASE

Ocular Therapeutix™ to Participate in November and December Investor C...

Ocular Therapeutix™ to Participate in November and December Investor Conferences BEDFORD, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor conferences in November and December, 2025. Jefferies Global Healthcare Conference in London:Fireside Chat Date: Tuesday, November 18, 2025Fireside Chat Time: 2:30 – 2:55 PM GMTPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: London, UK...

 PRESS RELEASE

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule...

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to one newly hired non-executive employee. The award was made as an inducement material to the individual’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity ...

 PRESS RELEASE

BRT Apartments Corp. Files Third Quarter 2025 Financial Statements

BRT Apartments Corp. Files Third Quarter 2025 Financial Statements GREAT NECK, N.Y., Nov. 06, 2025 (GLOBE NEWSWIRE) -- BRT APARTMENTS CORP. (NYSE:BRT), a real estate investment trust, announced today that it has filed its quarterly report on Form 10-Q for the quarter ended September 30, 2025, with the Securities and Exchange Commission. The financial statements and  can be accessed on the Company’s investor relations under the caption “Financials – Quarterly Results.” BRT is a real estate investment trust that owns, operates and, to a lesser extent, holds interests in joint ventures tha...

 PRESS RELEASE

Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and B...

Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights Recent Investor Day highlighted how AXPAXLI™ is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability Announced today that SOL-R achieved target randomization of 555 subjects Exceptional execution and retention in AXPAXLI wet AMD registrational program continue with topline data on track for SOL-1 in 1Q 2026 and SOL-R in 1H 2027 Registrational HELIOS program for AXPAXLI in NPDR expected to begin imminently using a novel primary endpoint Cash...

 PRESS RELEASE

Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in S...

Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R SOL-R, the second registrational trial of AXPAXLI™ in wet AMD, remains on track for topline data in 1H 2027 Together with SOL-1, these complementary trials are expected to form the basis of a potential NDA submission for AXPAXLI in wet AMD BEDFORD, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that its SOL-R registrational trial of AXPAXLI™ (also known as OTX-TKI) in...

 PRESS RELEASE

UMH PROPERTIES, INC. REPORTS RESULTS FOR THE THIRD QUARTER ENDED SEPTE...

UMH PROPERTIES, INC. REPORTS RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025 FREEHOLD, NJ, Nov. 03, 2025 (GLOBE NEWSWIRE) -- UMH Properties, Inc. (NYSE:UMH) (TASE:UMH) reported Total Income for the quarter ended September 30, 2025 of $66.9 million as compared to $60.7 million for the quarter ended September 30, 2024, representing an increase of 10%. Net Income Attributable to Common Shareholders amounted to $4.2 million or $0.05 per diluted share for the quarter ended September 30, 2025 as compared to Net Income Attributable to Common Shareholders of $8.2 million or $0.11 per dilut...

 PRESS RELEASE

Ocular Therapeutix™ to Report Third Quarter 2025 Financial Results on ...

Ocular Therapeutix™ to Report Third Quarter 2025 Financial Results on November 4, 2025 BEDFORD, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Tuesday, November 4, 2025 at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2025. Conference Call and Webcast Information: Date: Tuesday, November 4, 2025, at 8:00 AM ET Participant ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: October 25, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: October 21, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

BRT Apartments Corp: 1 director

A director at BRT Apartments Corp bought 7,000 shares at 14.961USD and the significance rating of the trade was 39/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: October 20, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: October 18, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch